EBioMedicine · 2025
Seizure detection using wearable electrocardiogram connected to a smartphone: a phase 3 clinical validation study.
Клиническое исследование III фазыСтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jeppesen Jesper, Christensen Jakob, Ahrenfeldt Petersen Oliver, Fenger Sarah, Armand Larsen Sidsel, Wüstenhagen Stephan, Wagner Stefan Rahr, Johansen Peter, Beniczky Sándor
Аннотация
BACKGROUND: Automated seizure detection is needed for patient safety and for objective seizure quantification. Wearable seizure detection devices hold great potential to improve patient care. Our objectives were to assess the accuracy of a wearable ECG-device connected to a smartphone, in detecting epileptic seizures in patients with autonomic ictal changes, and evaluate its capability to automatically determine impairment of consciousness.
METHODS: We conducted a phase 3, prospective, blinded, multicentre, clinical validation study of real-time seizure detection using a predefined algorithm. We recruited consecutive patients admitted to Epilepsy Monitoring Units. Eligible patients experienced seizures with autonomic ictal manifestations, defined as ictal heart rate change exceeding 50 beats per minute, inferred from the first recorded seizure. Patients wore an ECG-device connected to a smartphone. The algorithm, based on heart rate variability, used a personalised detection threshold determined from the first 24 h of recording. During daytime, seizure detection triggered automated behavioural-testing on the smartphone to confirm detection and assess consciousness.
FINDINGS: Of 101 enrolled patients, 36 experienced seizures, with 42 seizures recorded from 17 eligible patients. Overall sensitivity across all 42 seizures was 90·5% (95% CI: 77·4-97·3%), median sensitivity per patient was 100% (95% CI: 100-100%). All bilateral tonic-clonic seizures were detected, while sensitivity for other focal seizures was 82·6% (95% CI: 61·2-95·1%), median per patient: 100% (95% CI: 60-100%). Mean false alarm rate was 2·5/day (median per patient: 1·1/day, 95% CI: 0-2·8/day, zero during the night). Device deficiency time was 1·8% and signal loss was 4·5% (median per patient: 0·3% and 0·5% respectively). Use of the behavioural-testing application successfully cancelled all false alarms and accurately identified impairment of consciousness.
INTERPRETATION: The wearable ECG device connected to a smartphone accurately detected focal and generalised seizures, and assessed impairment of consciousness.
FUNDING: Independent Research Fund Denmark (grant number 0134-00400B).
METHODS: We conducted a phase 3, prospective, blinded, multicentre, clinical validation study of real-time seizure detection using a predefined algorithm. We recruited consecutive patients admitted to Epilepsy Monitoring Units. Eligible patients experienced seizures with autonomic ictal manifestations, defined as ictal heart rate change exceeding 50 beats per minute, inferred from the first recorded seizure. Patients wore an ECG-device connected to a smartphone. The algorithm, based on heart rate variability, used a personalised detection threshold determined from the first 24 h of recording. During daytime, seizure detection triggered automated behavioural-testing on the smartphone to confirm detection and assess consciousness.
FINDINGS: Of 101 enrolled patients, 36 experienced seizures, with 42 seizures recorded from 17 eligible patients. Overall sensitivity across all 42 seizures was 90·5% (95% CI: 77·4-97·3%), median sensitivity per patient was 100% (95% CI: 100-100%). All bilateral tonic-clonic seizures were detected, while sensitivity for other focal seizures was 82·6% (95% CI: 61·2-95·1%), median per patient: 100% (95% CI: 60-100%). Mean false alarm rate was 2·5/day (median per patient: 1·1/day, 95% CI: 0-2·8/day, zero during the night). Device deficiency time was 1·8% and signal loss was 4·5% (median per patient: 0·3% and 0·5% respectively). Use of the behavioural-testing application successfully cancelled all false alarms and accurately identified impairment of consciousness.
INTERPRETATION: The wearable ECG device connected to a smartphone accurately detected focal and generalised seizures, and assessed impairment of consciousness.
FUNDING: Independent Research Fund Denmark (grant number 0134-00400B).